Despite a substantial increase in consensus revenue growth forecasts and a sharply lower future P/E, Elutia’s consensus analyst price target has been reduced from $7.50 to $6.50.
What's in the News
- Elutia published a study showing its antibiotic-eluting CIED biologic envelope, EluPro, controls inflammation, supports vascularization, and promotes higher growth factor release, potentially reducing scarring and infection risks in implantable cardiac device patients.
- Researchers developed and published the first validated method for measuring antibiotic release from a biologic envelope, enabling faster, lower-cost product testing and development for the EluPro portfolio and satisfying critical FDA requirements for drug-device combination products.
Valuation Changes
Summary of Valuation Changes for Elutia
- The Consensus Analyst Price Target has significantly fallen from $7.50 to $6.50.
- The Future P/E for Elutia has significantly fallen from 42.58x to 24.15x.
- The Consensus Revenue Growth forecasts for Elutia has significantly risen from 48.3% per annum to 63.7% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.